21 April 1999 Applying fiber optical methods for toxicological testing in vitro
Author Affiliations +
Proceedings Volume 3603, Systems and Technologies for Clinical Diagnostics and Drug Discovery II; (1999) https://doi.org/10.1117/12.346746
Event: BiOS '99 International Biomedical Optics Symposium, 1999, San Jose, CA, United States
The new medical developments, e.g. immune therapy, patient oriented chemotherapy or even gene therapy, create a questionable doubt to the further requirement of animal test. Instead the call for humanitarian reproductive in vitro models becomes increasingly louder. Pharmaceutical usage of in vitro has a long proven history. In cancer research and therapy, the effect of chemostatica in vitro in the so-called oncobiogram is being tested; but the assays do not always correlate with in vivo-like drug resistance and sensitivity. We developed a drug test system in vitro, feasible for therapeutic drug monitoring by the combination of tissue cultivation in hollow fiber bioreactors and fiber optic sensors for monitoring the pharmaceutical effect. Using two fiber optic sensors - an optical oxygen sensor and a metabolism detecting Laserfluoroscope, we were able to successfully monitor the biological status of tissue culture and the drug or toxic effects of in vitro pharmaceutical testing. Furthermore, we developed and patented a system for monitoring the effect of minor toxic compounds which can induce Sick Building Syndrome.
© (1999) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Holger K. Maerz, Holger K. Maerz, Rainer Buchholz, Rainer Buchholz, Frank Emmrich, Frank Emmrich, Frank Fink, Frank Fink, Clive L. Geddes, Clive L. Geddes, Lutz Pfeifer, Lutz Pfeifer, Ferdinand Raabe, Ferdinand Raabe, Thomas-Helmut Scheper, Thomas-Helmut Scheper, Elizabeth Ulrich, Elizabeth Ulrich, Uwe Marx, Uwe Marx, } "Applying fiber optical methods for toxicological testing in vitro", Proc. SPIE 3603, Systems and Technologies for Clinical Diagnostics and Drug Discovery II, (21 April 1999); doi: 10.1117/12.346746; https://doi.org/10.1117/12.346746

Back to Top